| 2020-SINT-69102 | |
| Purdue University researchers have developed compounds that are anti-proliferative against multiple cancer cell types. Cancer results from genetic alterations that impose uncontrolled proliferation of cells. Therefore, developing molecules to debilitate cellular proliferation would prove an effective treatment for cancers. Purdue researchers optimized a synthetic method to quickly synthesize a library of compounds containing combined cancer drug scaffolds via a multi-component Povarov reaction. The researchers investigated the anti-proliferative effects of the compounds by a primary screen in the MDA-MB-231 triple-negative breast cancer cell line. Analogs of the most potent compounds were further tested against the NCI-60 cancer cell panel and exhibited anti-proliferative effects on melanoma, leukemia, breast, lung, and renal cancer cell lines with GI50 values at sub micromolar concentrations. These molecules are also promising because they have a high fraction of sp3 carbons increasing their drug like characteristics. The compounds' potency toward multiple cancer cell lines and drug like properties make them promising candidates for future therapeutic development. Advantages: -Combined Anti-Cancer Scaffold -Easily Synthesized Compounds -Increased Drug-Like Characteristics Applications: -Cancer Therapies -Cancer Relapse Therapies Related Publication: HSD1787, a Tetrahydro-3H-Pyrazolo[4,3-f]Quinoline Compound Synthesized via Povarov Reaction, Potently Inhibits Proliferation of Cancer Cell Lines at Nanomolar Concentrations ACS Omega 2020, 5, 37, 23799-23807 DOI: 10.1021/acsomega.0c03001 |
|
|
|
|
Dec 22, 2022
NATL-Patent
United States
(None)
(None)
Jul 1, 2021
PCT-Patent
WO
(None)
(None)
Jul 1, 2021
NATL-Patent
Europe
(None)
(None)
Jul 2, 2020
Provisional-Patent
United States
(None)
(None)
|
|
|
Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org |
